NO20091198L - Azabenzotiofenylforbindelser og anvendelser derav - Google Patents

Azabenzotiofenylforbindelser og anvendelser derav

Info

Publication number
NO20091198L
NO20091198L NO20091198A NO20091198A NO20091198L NO 20091198 L NO20091198 L NO 20091198L NO 20091198 A NO20091198 A NO 20091198A NO 20091198 A NO20091198 A NO 20091198A NO 20091198 L NO20091198 L NO 20091198L
Authority
NO
Norway
Prior art keywords
compounds
azabenzothiophenyl
treat
methods
relates
Prior art date
Application number
NO20091198A
Other languages
English (en)
Norwegian (no)
Inventor
Mark S Stanley
Hazel Joan Dyke
Stephen Price
Karen Williams
Liang Bao
John Gary Montana
Pascal Pierre Savy
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38800915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091198(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20091198L publication Critical patent/NO20091198L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20091198A 2006-08-21 2009-03-20 Azabenzotiofenylforbindelser og anvendelser derav NO20091198L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83916306P 2006-08-21 2006-08-21
US87160006P 2006-12-22 2006-12-22
US91762407P 2007-05-11 2007-05-11
PCT/US2007/076340 WO2008024724A1 (en) 2006-08-21 2007-08-20 Aza-benzothiophenyl compounds and methods of use

Publications (1)

Publication Number Publication Date
NO20091198L true NO20091198L (no) 2009-05-20

Family

ID=38800915

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091198A NO20091198L (no) 2006-08-21 2009-03-20 Azabenzotiofenylforbindelser og anvendelser derav

Country Status (16)

Country Link
US (1) US7893085B2 (es)
EP (1) EP2069359B1 (es)
JP (1) JP5349306B2 (es)
KR (1) KR101475088B1 (es)
AR (1) AR062469A1 (es)
AU (1) AU2007286807B2 (es)
BR (1) BRPI0714629A2 (es)
CA (1) CA2660963A1 (es)
CL (1) CL2007002431A1 (es)
ES (1) ES2528797T3 (es)
IL (1) IL197060A (es)
MX (1) MX2009001875A (es)
NO (1) NO20091198L (es)
PE (2) PE20120049A1 (es)
TW (1) TWI426078B (es)
WO (1) WO2008024724A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009001878A (es) * 2006-08-21 2009-03-03 Genentech Inc Compuestos de aza-benzofuranilo y metodos de uso.
JP5651125B2 (ja) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Mek阻害剤に対する耐性を付与するmek突然変異
MX360932B (es) 2010-02-25 2018-11-21 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
CN103038364A (zh) 2010-03-09 2013-04-10 达纳-法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
EP2844655A1 (en) 2012-05-02 2015-03-11 Lupin Limited Substituted pyridine compounds as crac modulators
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
CA3008171A1 (en) * 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
EP3443114A1 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Diagnostic and therapeutic methods for cancer
US10988483B2 (en) * 2017-05-19 2021-04-27 Nflection Therapeutics, Inc. Fused heteroaromatic-aniline compounds for treatment of dermal disorders
KR102642411B1 (ko) 2017-05-19 2024-02-28 엔플렉션 테라퓨틱스, 인코포레이티드 피부병 치료를 위한 피롤로피리딘-아닐린 화합물
IL310023A (en) 2017-06-21 2024-03-01 SHY Therapeutics LLC Compounds interacting with the RAS superfamily for the treatment of cancer, inflammation, RAS pathology and fibrotic diseases
EP3679159A1 (en) 2017-09-08 2020-07-15 H. Hoffnabb-La Roche Ag Diagnostic and therapeutic methods for cancer
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
AU2019383311A1 (en) 2018-11-20 2021-06-10 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
JP2022526901A (ja) 2019-03-19 2022-05-27 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 駆虫性アザベンゾチオフェンおよびアザベンゾフラン化合物
PE20231205A1 (es) 2020-05-29 2023-08-17 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos como anthelminticos
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328920A (en) * 1991-04-17 1994-07-12 Hoechst-Roussel Pharmaceuticals Incorporated Substituted (pyridinylamino)-indoles
US5472978A (en) 1991-07-05 1995-12-05 Merck Sharp & Dohme Ltd. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
US5214204A (en) * 1991-07-19 1993-05-25 Abbott Laboratories Arylamidoalkyl-n-hydroxyurea compounds having lipoxygenase inhibitory activity
ATE147386T1 (de) * 1991-08-12 1997-01-15 Takeda Chemical Industries Ltd Kondensierte pyrimidinderivate, ihre herstellung und ihre verwendung als antitumormittel
EP0545478A1 (en) * 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
JPH05345780A (ja) * 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
US5852046A (en) * 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
US5350748A (en) * 1993-08-18 1994-09-27 Warner-Lambert Company 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion
DE4425609A1 (de) * 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
JP4306806B2 (ja) 1997-04-24 2009-08-05 ダウ・アグロサイエンス・エル・エル・シー 有害生物防除性 3―(置換フェニル)―5―(チエニルまたはフリル)―1,2,4―トリアゾール
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
FR2777886B1 (fr) * 1998-04-27 2002-05-31 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0982304B1 (en) 1998-06-30 2002-10-02 Eli Lilly And Company Piperidine derivatives having effects on serotonin related systems
EP1100501A4 (en) 1998-06-30 2002-12-04 Lilly Co Eli PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN
US6465453B1 (en) 1998-06-30 2002-10-15 Eli Lilly And Company Azepine derivatives having effects on serotonin related systems
US6410562B1 (en) * 1998-12-18 2002-06-25 Eli Lilly And Company Hypoglycemic imidazoline compounds
JP2000204079A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
ID30439A (id) * 1999-01-13 2001-12-06 Warner Lambert Co Benzoheterosiklus dan penggunaannya sebagai penghambat mek
FR2799756B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR027133A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
SI1301472T1 (sl) * 2000-07-19 2014-05-30 Warner-Lambert Company Llc Oksigenirani estri 4-jodo fenilamino benzihidroksamskih kislin
DE10110750A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6653346B1 (en) * 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
AU2003217275A1 (en) 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Azabicyclic compounds for the treatment of disease
TW200406203A (en) * 2002-03-13 2004-05-01 Array Biopharma Inc N3 alkylated banzimidazole derivatives as MEK inhibitors
PT2275102E (pt) * 2002-03-13 2015-10-27 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
US20040009976A1 (en) * 2002-04-30 2004-01-15 Kumiko Takeuchi Hypoglycemic imidazoline compounds
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
ES2294330T3 (es) 2002-08-02 2008-04-01 MERCK & CO., INC. Derivados de furo(2,3-b)piridina sustituidos.
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
JP2005104838A (ja) 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
EP1663242B1 (en) 2003-08-07 2011-04-27 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
DE10351436A1 (de) 2003-11-04 2005-06-09 Merck Patent Gmbh Verwendung von Thienopyrimidinen
ES2299906T3 (es) 2003-11-25 2008-06-01 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisomas.
CA2545506A1 (en) 2003-12-19 2005-06-30 Biovitrum Ab Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
CA2545821C (en) 2003-12-22 2010-09-21 Basilea Pharmaceutica Ag Aroylfuranes and aroylthiophenes
JP2007516275A (ja) 2003-12-23 2007-06-21 ファイザー・プロダクツ・インク 認知増強および精神病性障害のための治療的組合せ
EP1869052A1 (en) * 2005-04-06 2007-12-26 AstraZeneca AB Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
RU2008112313A (ru) * 2005-09-01 2009-10-10 Эррэй Биофарма Инк. (Us) Соединения ингибиторы raf и способы их применения
MX2009001878A (es) * 2006-08-21 2009-03-03 Genentech Inc Compuestos de aza-benzofuranilo y metodos de uso.
CN101553492A (zh) 2006-08-31 2009-10-07 阵列生物制药公司 Raf抑制剂化合物及其使用方法

Also Published As

Publication number Publication date
IL197060A (en) 2014-12-31
TW200823222A (en) 2008-06-01
JP2010501584A (ja) 2010-01-21
PE20081359A1 (es) 2008-11-27
EP2069359B1 (en) 2014-11-12
EP2069359A1 (en) 2009-06-17
US20080081821A1 (en) 2008-04-03
BRPI0714629A2 (pt) 2013-05-07
IL197060A0 (en) 2009-11-18
MX2009001875A (es) 2009-03-02
AR062469A1 (es) 2008-11-12
AU2007286807A1 (en) 2008-02-28
PE20120049A1 (es) 2012-02-16
KR101475088B1 (ko) 2014-12-23
JP5349306B2 (ja) 2013-11-20
AU2007286807B2 (en) 2013-03-21
WO2008024724A1 (en) 2008-02-28
CA2660963A1 (en) 2008-02-28
US7893085B2 (en) 2011-02-22
KR20090047538A (ko) 2009-05-12
CL2007002431A1 (es) 2008-03-14
ES2528797T3 (es) 2015-02-12
TWI426078B (zh) 2014-02-11

Similar Documents

Publication Publication Date Title
NO20091197L (no) Azabenzofuranylforbindelser og anvendelser derav
NO20091198L (no) Azabenzotiofenylforbindelser og anvendelser derav
DK2231662T3 (da) 8-Anilinoimidazopyridiner og deres anvendelse som anticancer- og/eller antiinflammatoriske midler
WO2010003022A8 (en) Isoindolone derivatives as mek kinase inhibitors and methods of use
MY158829A (en) 5-anilinoimidazopyridines and methods of use
WO2008157179A3 (en) N-substituted azaindoles and methods of use
NO20074473L (no) RAF-inhibitorforbindelser og -fremgangsmater
WO2009111278A3 (en) Raf inhibitor compounds and methods of use thereof
SG178986A1 (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
UA111933C2 (uk) Піролопіридини як інгібітори кінази
NO20076553L (no) RAF-inhibitorforbindelser og fremgangsmater for anvendelse derav
UA111756C2 (uk) Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EA200801716A1 (ru) Тиазольные соединения и их применение
NO20081595L (no) Raf-inhibitorforbindelser og fremgangsmater for anvendelse derav
BR112014021634A8 (pt) inibidores de serina/treonina quinase,composições que os compreendem, seus usos e seus processos de preparação, e método de inibir a atividade da proteína quinase erk em uma célula
PH12013502369A1 (en) Diazacarbazoles and methods of use
MX2014005282A (es) Compuestos de 8-fluoroftalazin-1 (2h) -ona.
WO2011025938A3 (en) Raf inhibitor compounds and methods of use thereof
ECSP10010507A (es) Pirazolo (3, 4-b) piridina inhibidores de raf
WO2009012109A3 (en) Cyanine-containing compounds for cancer imaging and treatment
NO20084928L (no) Farmasoytiske sammensetninger
WO2010105008A3 (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
MX2010001993A (es) Metodos y composiciones para diagnosticar una enfermedad.
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application